Literature DB >> 10353760

Mechanisms of apoptosis in T cells from patients with renal cell carcinoma.

R G Uzzo1, P Rayman, V Kolenko, P E Clark, T Bloom, A M Ward, L Molto, C Tannenbaum, L J Worford, R Bukowski, R Tubbs, E D Hsi, N H Bander, A C Novick, J H Finke.   

Abstract

Tumors may escape immune recognition and destruction through the induction of apoptosis in activated T lymphocytes. Results from several laboratories suggest that FasL (L/CD95L) expression in tumors may be responsible for this process. In this study of patients with renal cell carcinoma (RCC), we provide evidence for two mechanisms of T-cell apoptosis. One mechanism involves the induction of apoptosis via FasL expression in tumor cells. This is supported by several observations, including the fact that tumor cells in situ as well as cultured cell lines expressed FasL mRNA and protein by a variety of techniques. The FasL in RCC is functional because in coculture experiments, FasL+ tumors induced apoptosis in Fas-sensitive Jurkat T cells and in activated peripheral blood T cells but not in resting peripheral blood T cells. Most importantly, antibody to FasL partially blocked apoptosis of the activated T cells. Moreover, Fas was expressed by T cells derived from the peripheral blood (53% median) and tumor (44.3% median) of RCC patients. Finally, in situ staining for DNA breaks demonstrated apoptosis in a subset of T cells infiltrating renal tumors. These studies also identified a second mechanism of apoptosis in RCC patient peripheral T cells. Whereas these cells did not display DNA breaks when freshly isolated or after culture for 24 h in medium, peripheral blood T cells from RCC patients underwent activation-induced cell death after stimulation with either phorbol 12-myristate 13-acetate/ionomycin or anti-CD3/CD28 antibodies. Apoptosis mediated by exposure to FasL in tumor cells or through T-cell activation may contribute to the failure of RCC patients to develop an effective T-cell-mediated antitumor response.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353760

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  25 in total

1.  Novel roles of c-Met in the survival of renal cancer cells through the regulation of HO-1 and PD-L1 expression.

Authors:  Murugabaskar Balan; Eduardo Mier y Teran; Ana Maria Waaga-Gasser; Martin Gasser; Toni K Choueiri; Gordon Freeman; Soumitro Pal
Journal:  J Biol Chem       Date:  2015-02-02       Impact factor: 5.157

2.  Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells.

Authors:  R G Uzzo; P Rayman; V Kolenko; P E Clark; M K Cathcart; T Bloom; A C Novick; R M Bukowski; T Hamilton; J H Finke
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

3.  Acute myeloid leukaemia cells secrete a soluble factor that inhibits T and NK cell proliferation but not cytolytic function--implications for the adoptive immunotherapy of leukaemia.

Authors:  J K Orleans-Lindsay; L D Barber; H G Prentice; M W Lowdell
Journal:  Clin Exp Immunol       Date:  2001-12       Impact factor: 4.330

Review 4.  Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.

Authors:  Peter A Cohen; Jennifer S Ko; Walter J Storkus; Christopher D Spencer; Judy M Bradley; Jessica E Gorman; Dustin B McCurry; Soroya Zorro-Manrique; Anna Lucia Dominguez; Latha B Pathangey; Patricia A Rayman; Brian I Rini; Sandra J Gendler; James H Finke
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

5.  Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.

Authors:  R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-29       Impact factor: 11.205

6.  Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes.

Authors:  Julia Diegmann; Kerstin Junker; Ivan F Loncarevic; Susanne Michel; Bettina Schimmel; Ferdinand von Eggeling
Journal:  Neoplasia       Date:  2006-11       Impact factor: 5.715

Review 7.  Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.

Authors:  Paulo C Rodríguez; Augusto C Ochoa
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

Review 8.  Signaling defects in anti-tumor T cells.

Authors:  Alan B Frey; Ngozi Monu
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

9.  Altered pattern of major histocompatibility complex expression in renal carcinoma: tumor-specific expression of the nonclassical human leukocyte antigen-G molecule is restricted to clear cell carcinoma while up-regulation of other major histocompatibility complex antigens is primarily distributed in all subtypes of renal carcinoma.

Authors:  El Chérif Ibrahim; Yves Allory; Frédéric Commo; Bernard Gattegno; Patrice Callard; Pascale Paul
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

10.  Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction.

Authors:  Soumika Biswas; Kaushik Biswas; Amy Richmond; Jennifer Ko; Sankar Ghosh; Matthew Simmons; Patricia Rayman; Brian Rini; Inderbir Gill; Charles S Tannenbaum; James H Finke
Journal:  J Immunol       Date:  2009-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.